ArticleBiosensors2024
Gold-Graphene Quantum Dot Hybrid Nanoparticle for Smart Diagnostics of Prostate Cancer.
Article in Biosensors, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Quantum Dots: Catalysts for a New Era of Precision Medicine and Biomedical Innovation.Journal of fluorescence · 2026Review
- Recent progress in biowaste-derived carbon dots for cancer theranostics toward a green solution to toxic metal quantum dots.Discover nano · 2025Review
- Affordable ultrasensitive electrochemical detection of PCA3 for early prostate cancer diagnosis.Scientific reports · 2025Article
- Graphene-Based Biosensors: Enabling the Next Generation of Diagnostic Technologies-A Review.Biosensors · 2025Review
- Nanomaterial-enhanced biosensors for polycystic ovarian syndrome diagnosis and pathophysiological insights.Mikrochimica acta · 2025Review
- Quantum Dot-Enabled Biosensing for Prostate Cancer Diagnostics.Nanomaterials (Basel, Switzerland) · 2025Review
- Biomedical Applications of Metal-Organic Frameworks Revisited.Industrial & engineering chemistry research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is one of the most prevalent cancers afflicting men worldwide, often detected at advanced stages, leading to increased mortality rates. Addressing this challenge, we present an innovative approach employing electrochemical biosensing for early-stage prostate cancer detection. This study used Indium-Tin Oxide (ITO) as a substrate and a deposited gold-graphene quantum dot (Au-GQD) nanohybrid to establish electrochemical sensing platforms for DNA-hybridization assays. A capturing DNA probe, PCA3, was covalently immobilized on the surface of the Au-GQDs and deposited electrochemically onto the ITO electrode surface. The Au-GQDs enabled the capturing of the target PCA3 biomarker probe. The sensor achieved a limit of detection (LoD) of up to 211 fM and presented a linear detection range spanning 1 µM to 100 fM. A rapid 5-min response time was also achieved. The tested shelf life of the pre-immobilized sensor was approximately 19 ± 1 days, with pronounced selectivity for its intended target amidst various interferants. The sensing device has the potential to revolutionize prostate cancer management by facilitating early-stage detection and screening with enhanced treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.